Table 2.
Clinical features of RCCEP.
| Items | Camrelizumab monotherapy (N = 670) | Camrelizumab plus apatinib (N = 296) | Camrelizumab plus chemotherapy (N = 339) |
|---|---|---|---|
| Grade of RCCEP, n/N (%) | |||
| All grade | 516/670 (77.0%) | 70/296 (23.6%) | 230/339 (67.8%) |
| Grade 1 | 434/670 (64.8%) | 57/296 (19.3%) | 185/339 (54.6%) |
| Grade 2 | 80/670 (11.9%) | 11/296 (3.7%) | 41/339 (12.1%) |
| Grade 3 | 2/670 (0.3%) | 2/296 (0.7%) | 4/339 (1.2%) |
| Time to onset (months), median (IQR) | 0.8 (0.6–1.2) | 5.0 (2.7–8.0) | 1.6 (1.0–4.2) |
| Duration of RCCEP lesions (months), median (IQR) | 4.8 (2.6–8.8) | 4.4 (1.7–8.9) | 7.2 (4.1–14.3) |
| RCCEP remission rate, n/N1 (%) | 332/516 (64.3%) | 46/70 (65.7%) | 110/230 (47.8%) |
| Time to remission of RCCEP (months), median (IQR) | 4.2 (2.5–7.6) | 3.0 (1.2–5.6) | 6.2 (3.6–9.7) |
N is the number of patients in the group; N1 is the number of patients with RCCEP in the group.
IQR, interquartile range; RCCEP, reactive cutaneous capillary endothelial proliferation.